Drug intelligence / Profile preview

JS101

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**JS101** is an investigational **small-molecule pan-cyclin-dependent kinase inhibitor** being developed by **Junshi Biosciences** for oncology. Public pipeline materials identify the program as targeting **CDKs** and position it within the company's anticancer small-molecule portfolio, with external drug-database summaries indicating **Phase 1** clinical development and reported interest in tumors including **breast cancer** and **lymphoma**. The precise CDK isoform selectivity, formulation, and route of administration have not been clearly disclosed in the sources reviewed.

Targets

CDK (CDK family)

Beyond the preview

Go deeper on JS101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS101.

Explore the full profile